Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Journal of Occupational and Environmental Medicine
|
September 12, 2017
Methodology for ACOEM's Occupational Medicine Practice Guidelines-2017 Revision
Jeffrey S Harris, Michael S Weiss, Nelson S Haas, et al.
Biotechnology and Bioengineering
|
September 3, 2010
Cellular arrays for large-scale analysis of transcription factor activity
Abigail D Bellis, Beatriz Peňalver-Bernabé, Michael S Weiss, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 1, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox, Amy E Lovett-Racke, Matthew Gormley, et al.
British Journal of Haematology
|
December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Journal of Occupational and Environmental Medicine
|
January 30, 2019
Diagnostic Tests for Low Back Disorders
Kurt T Hegmann, Russell Travis, Roger M Belcourt, et al.
The Lancet. Oncology
|
February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A Burris, Ian W Flinn, Manish R Patel, et al.
The Lancet. Haematology
|
February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Journal of Occupational and Environmental Medicine
|
December 7, 2021
Reply to Sayeed et al
Russell Travis, Gunnar B J Andersson, Roger M Belcourt, et al.
Journal of Occupational and Environmental Medicine
|
June 27, 2022
Reply to Sayeed et al's Reply to Reply
Eugene J Carragee, Gunnar B J Andersson, Roger M Belcourt, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Journal of Occupational and Environmental Medicine
|
September 12, 2017
Methodology for ACOEM's Occupational Medicine Practice Guidelines-2017 Revision
Jeffrey S Harris, Michael S Weiss, Nelson S Haas, et al.
Biotechnology and Bioengineering
|
September 3, 2010
Cellular arrays for large-scale analysis of transcription factor activity
Abigail D Bellis, Beatriz Peňalver-Bernabé, Michael S Weiss, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 1, 2020
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox, Amy E Lovett-Racke, Matthew Gormley, et al.
British Journal of Haematology
|
December 17, 2016
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff P Sharman, Charles M Farber, Daruka Mahadevan, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Journal of Occupational and Environmental Medicine
|
January 30, 2019
Diagnostic Tests for Low Back Disorders
Kurt T Hegmann, Russell Travis, Roger M Belcourt, et al.
The Lancet. Oncology
|
February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
Howard A Burris, Ian W Flinn, Manish R Patel, et al.
The Lancet. Haematology
|
February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Journal of Occupational and Environmental Medicine
|
December 7, 2021
Reply to Sayeed et al
Russell Travis, Gunnar B J Andersson, Roger M Belcourt, et al.
Journal of Occupational and Environmental Medicine
|
June 27, 2022
Reply to Sayeed et al's Reply to Reply
Eugene J Carragee, Gunnar B J Andersson, Roger M Belcourt, et al.
Page
of 4